BR112023000220A2 - Formulações de longa ação - Google Patents

Formulações de longa ação

Info

Publication number
BR112023000220A2
BR112023000220A2 BR112023000220A BR112023000220A BR112023000220A2 BR 112023000220 A2 BR112023000220 A2 BR 112023000220A2 BR 112023000220 A BR112023000220 A BR 112023000220A BR 112023000220 A BR112023000220 A BR 112023000220A BR 112023000220 A2 BR112023000220 A2 BR 112023000220A2
Authority
BR
Brazil
Prior art keywords
long
pharmaceutical compositions
action formulations
formulations
action
Prior art date
Application number
BR112023000220A
Other languages
English (en)
Inventor
Holm René
Caroline F Vervoort Iwan
Dong Wenyu
Colombo Miriam
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112023000220A2 publication Critical patent/BR112023000220A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

FORMULAÇÕES DE LONGA AÇÃO. A presente invenção refere-se a composições farmacêuticas para administração por injeção intramuscular ou subcutânea, que compreendem micro ou nanopartículas do composto de bedaquilina anti-TB, suspensas em um carreador aquoso farmaceuticamente aceitável, e que compreendem PEG4000 como um modificador de superfície, e o uso de tais composições farmacêuticas no tratamento e profilaxia de uma infecção micobacteriana patogênica.
BR112023000220A 2020-07-09 2021-07-08 Formulações de longa ação BR112023000220A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20185105 2020-07-09
PCT/EP2021/068956 WO2022008643A1 (en) 2020-07-09 2021-07-08 Long-acting formulations

Publications (1)

Publication Number Publication Date
BR112023000220A2 true BR112023000220A2 (pt) 2023-01-31

Family

ID=71575093

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000220A BR112023000220A2 (pt) 2020-07-09 2021-07-08 Formulações de longa ação

Country Status (12)

Country Link
US (1) US20230241051A1 (pt)
EP (1) EP4178546A1 (pt)
JP (1) JP2023533014A (pt)
KR (1) KR20230038521A (pt)
CN (1) CN115867259A (pt)
AU (1) AU2021303490A1 (pt)
BR (1) BR112023000220A2 (pt)
CA (1) CA3182425A1 (pt)
CO (1) CO2023001340A2 (pt)
MX (1) MX2023000439A (pt)
PE (1) PE20231296A1 (pt)
WO (1) WO2022008643A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023183276A1 (en) * 2022-03-22 2023-09-28 University Of Southern California Adjunctive treatment of mycobacterial diseases
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
EP1527050B1 (en) 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
EP1626742A1 (en) 2003-05-22 2006-02-22 Elan Pharma International Limited Sterilization of dispersions of nanoparticulate active agents with gamma radiation
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
EP1888604B1 (en) 2005-05-25 2012-03-14 Janssen Pharmaceutica NV Process for preparing (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
BRPI0713334B1 (pt) 2006-06-23 2024-02-20 Janssen Sciences Ireland Uc Uso de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrila para tratar ou prevenir infecção por HIV
US9421194B2 (en) * 2010-04-05 2016-08-23 Rutgers, The State University Of New Jersey Lung targeting dual drug delivery system
LT2696848T (lt) 2011-04-15 2020-09-10 Janssen Pharmaceutica N.V. Liofilizuotos vaisto nanosuspensijos
CN115252548A (zh) 2017-07-14 2022-11-01 詹森药业有限公司 长效配制品

Also Published As

Publication number Publication date
CA3182425A1 (en) 2022-01-13
CO2023001340A2 (es) 2023-02-27
US20230241051A1 (en) 2023-08-03
EP4178546A1 (en) 2023-05-17
PE20231296A1 (es) 2023-08-22
MX2023000439A (es) 2023-02-09
JP2023533014A (ja) 2023-08-01
KR20230038521A (ko) 2023-03-20
CN115867259A (zh) 2023-03-28
AU2021303490A1 (en) 2023-03-09
WO2022008643A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
BR112023000220A2 (pt) Formulações de longa ação
AR061620A1 (es) Suspensiones acuosas de tmc278
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
PH12020500076A1 (en) Long-acting formulations
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
UY37168A (es) Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles
BR112015013695A2 (pt) composição farmacêutica, e, métodos para tratamento e para prevenção de uma infecção por hiv
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
CO2022014876A2 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
BR112023001792A2 (pt) Combinações para o tratamento de câncer
BR112017001093A2 (pt) formulação aquosa compreendendo paracetamol e ibuprofeno
BR112021024651A2 (pt) Composição farmacêutica parenteral isotônica, método para melhoria da estabilidade química da dita composição e uso de manitol ou um sal
BR112021019859A2 (pt) Vacinas de circovírus suíno tipo 3 (pcv3) e produção e seus usos
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
CL2018002705A1 (es) Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales
BR112022002444A2 (pt) Técnicas de sobremoldagem e artigos relacionados produzidos por estas
BR112021009353A2 (pt) Formulações farmacêuticas para administração subcutânea
BR112019002125A2 (pt) composição de comprimidos de alta carga de fármacos para o tratamento do hiv
EA202090287A1 (ru) Составы пролонгированного действия
BR112023000915A2 (pt) Composição de vacina para prevenir síndrome respiratória aguda grave por infecção do coronavírus 2.
CL2022003689A1 (es) Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4)